Tetra Bio-Pharma (TBP.T) announced today that Health Canada has accepted the Company’s New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug…
Tetra Bio-Pharma
Tetra Bio-Pharma (TBP.T) announced they are accelerating their PLENITUDE Phase II clinical trial, which is studying QIXLEEF. QIXLEEF is Tetra’s proprietary drug formulation which contains THC and CBD and…
Tetra Bio-Pharma (TBP.T) has announced the start of the REBORN1© clinical trial, designed to evaluate the effect of QIXLEEF™, the Company’s inhaled proprietary drug formulation. During this study, QIXLEEF™…
Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, has announced that is has signed a Definitive Agreement with DanCann Pharma for the exclusive distribution of Reduvo™…
Another day, another Tetra Bio-Pharma (TBP.T) news release. A day after they were granted a Drug Establishment Licence by Health Canada for their REDUVO soft gel capsules, Tetra announced…